GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK Interest Income
Income earned on cash, deposits, and investments held by the company.
GSK plcNYSE: GSK
Interest Income · Q2 FY2026 · quarter ended Jun 2026
Interest income grows, but more slowly than its trailing trend
Q2 FY2026 interest income of £58M rose 16.0% year over year, behind the +24.7% change in trailing-twelve-month interest income. Sequentially, it rose 163.6% from the prior quarter. Over 3 fiscal years it compounded at -4.5% a year.
Context
- Interest income amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +16.0% toward the trailing-twelve-month pace of +24.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
GBP · from the income statement
- Latest · FY2025
- 56M GBP
- Year-over-year change
- -16.9%
- 4-year CAGR
- +18.9%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 56M | -16.9% |
| FY2024 | 2024-12-31 | 67.39M | +68.5% |
| FY2023 | 2023-12-31 | 40M | -37.8% |
| FY2022 | 2022-12-31 | 64.27M | +129.5% |
| FY2021 | 2021-12-31 | 28M | — |
Interest Income vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.7% is the highest of 8, against a peer median of -37.7%.
- Interest income amounts to 0.3% of revenue for GSK, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 11.65B DKK | -17.0% | +74.5% | 3.5% | |
| LTM Sep 2026 | $685M USD | -37.7% | +29.2% | 0.7% | |
| LTM Jun 2026 | $532M USD | -9.1% | +33.9% | 0.8% | |
| LTM Sep 2026 | $342.11M USD | +13.7% | +64.4% | 0.6% | |
| LTM Jun 2026 | €274.69M EUR | -50.8% | +25.1% | 0.6% | |
| LTM Jun 2026 | $200M USD | -55.7% | +29.8% | 0.3% | |
| LTM Jun 2026 | £106M GBP | +24.7% | -4.5% | 0.3% | |
| LTM Jun 2026 | $65M USD | -64.0% | +34.6% | 0.1% | |
| LTM Jun 2026 | $0 USD | — | -0.2% | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding GSK) | — | -37.7% | +31.8% | 0.6% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 24.7B | 29.32B | 30.33B | 31.38B | 32.67B |
| Cost of Revenue | 8.16B | 9.55B | 8.57B | 9.05B | 9.02B |
| Gross Profit | 16.53B | 19.77B | 21.76B | 22.33B | 23.65B |
| Gross Margin | 66.9% | 67.4% | 71.8% | 71.2% | 72.4% |
| Research & Development | 5.02B | 5.49B | 6.22B | 6.4B | 7.53B |
| Selling, General & Admin | 7.07B | 8.37B | 9.39B | 11.02B | 9.09B |
| Operating Expenses | 12.18B | 13.34B | 15.02B | 18.31B | 15.31B |
| Depreciation & Amortization | 2.12B | 2.15B | 2.29B | 2.55B | 2.31B |
| EBITDA | 6.49B | 8.6B | 9.08B | 6.67B | 10.4B |
| EBITDA Margin | 26.3% | 29.3% | 29.9% | 21.3% | 31.8% |
| Operating Income | 4.36B | 6.43B | 6.75B | 4.02B | 8.34B |
| Operating Margin | 17.6% | 21.9% | 22.2% | 12.8% | 25.5% |
| Interest Income | 28M | 64.27M | 40M | 67.39M | 56M |
| Interest Expense | 784M | 855.53M | 775M | 657.58M | 687M |
| Other Income / Expenses | (758M) | (805M) | (681M) | (544M) | (937M) |
| Income Before Tax | 3.6B | 5.63B | 6.06B | 3.48B | 7.4B |
| Pre-Tax Margin | 14.6% | 19.2% | 20.0% | 11.1% | 22.7% |
| Income Tax Expense | 83M | 707M | 756M | 526M | 1.11B |
| Net Income | 4.39B | 14.96B | 4.93B | 2.58B | 5.72B |
| Net Margin | 17.8% | 51.0% | 16.2% | 8.2% | 17.5% |
| EPS (Basic) | 2.74 | 7.44 | 2.44 | 1.26 | 2.82 |
| EPS (Diluted) | 2.70 | 7.32 | 2.40 | 1.24 | 2.78 |
| Weighted Avg Shares | 1.6B | 2.01B | 2.03B | 2.04B | 2.03B |
| Weighted Avg Shares (Diluted) | 1.62B | 2.04B | 2.06B | 2.07B | 2.06B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.